IP Library Granted Patent US 10,001,469
Granted Patent B2
US 10,001,469 · App. 14/823,378 · Granted Jun 19, 2018

Use of GPR83 to identify pruritus-related substances

Inventors: Toshikazu Nishimori (Miyazaki, JP); Rumi Nakayama (Miyazaki, JP)
Assignee: University of Miyazaki
G01N33/5008A61K38/08A61K49/0008C07K7/06C07K14/52C07K14/705C07K14/715C12N15/1138A61K38/00C12N2310/14G01N2500/04G01N2800/2842G01N2800/7095
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,001,469
App. No.
14/823,378
Granted
Jun 19, 2018
Kind
B2
Abstract

The present invention provides a peptide having antagonist activity against SP, pain control activity, anti-inflammation activity, and anti-pruritic activity. The present invention further provides a method for searching for a therapeutic agent for pain, a therapeutic agent for inflammation, and a therapeutic agent for pruritus using G protein coupled receptor (GPR) 83, which is an HK-1 specific receptor.

Claims (17)

1. A method for evaluating, in vivo, a test substance in a non-human animal, comprising:

administering a GPR83 inhibitor to a first non-human animal and a second non-human animal, wherein the GPR83 inhibitor is selected from the group consisting of a polypeptide, an antibody, an antisense inhibitor, and an siRNA;

administering a first test substance to the first non-human animal;

administering a control substance to the second non-human animal;

comparing itching behavior in the first non-human animal and itching behavior in the second non-human animal; and

evaluating whether or not the first test substance is a pruritus-related substance based on an increase or decrease in itching behavior.

2. The method of claim 1 , further comprising:

determining that the first test substance is a pruritus inhibiting substance if the itching behavior in the first non-human animal is suppressed.

3. A method for evaluating, in vivo, a test substance in a non-human animal, comprising:

administering a GPR83 inhibitor to a first non-human animal wherein the GPR83 inhibitor is selected from the group consisting of a polypeptide, an antibody, an antisense inhibitor, and an siRNA;

administering a test substance to the first non-human animal;

administering the test substance to a second non-human animal in which the GPR83 function is not inhibited;

administering a compound that induces itching to the first non-human animal and the second non-human animal; and

comparing itching behavior in the first non-human animal and itching behavior in the second non-human animal;

wherein a decrease in the itching behavior in the first non-human animal compared to the second non-human animal indicates that the test substance is an agonist of GPR83, and

wherein an increase in the itching behavior in the first non-human animal compared to the second non-human animal indicates that the test substance is an antagonist of GPR83.

4. The method of claim 3 , wherein the compound that induces itching is selected from the group consisting of histamine and serotonin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2015
From: NISHIMORI, TOSHIKAZU; NAKAYAMA, RUMI
To: UNIVERSITY OF MIYAZAKI
Reel/Frame 037352/0775 →
Priority Claims (1)
JP 2010-191039 · Aug 27, 2010 · national
Continuity (3)
Division 13819142
Provisional Application 61471338 · Apr 4, 2011
Related Publication 20160033478A1 · Feb 4, 2016